Discover why Pfizer stock may be set for a bull run by 2026 with key wins, strong Q3 earnings, and growth drivers.

Pfizer's CEO thinks his company will make big waves in the weight loss market. Eli Lilly does have a strong hold on the ...

Pfizer offers strong dividends, solid cash flow coverage, discounted value and key risks from patent cliffs, pricing and ...

Global Biotech is surging as policy fears fade and innovation takes centre stage. Here’s what’s driving the comeback into ...

The Biotech Growth Trust PLC - Half-year Financial Report ...

A healthcare worker prepares a shot of the Pfizer COVID-19 vaccine in La Paz, Bolivia, Jan. 7. WASHINGTON — The most widely used COVID-19 vaccines may offer a surprise benefit for some cancer patients ...

Strong financial position with cash, cash equivalents and marketable securities of $93.7M Moderna litigation U.S. trial scheduled for March 2026;Favorable claim construction ruling in Pfizer-BioNTech ...

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today reported financial ...

Third quarter 2025 revenue of $9.5 million, up 10% year-over-year Amended credit agreement with Avenue Capital Group which strengthens our balance sheet with ...

Ligand is increasing its 2025 full year financial guidance. The Company now expects total core revenue of $225 million to $235 million (previously $200 million to $225 million) and core adjusted ...